Health Care

A look at symptoms, diagnosis, treatments and current MDA-supported research into this complex autoimmune disorder

posted on June 15, 2015 - 1:01pm
In recognition of June being National Myasthenia Gravis Awareness Month, MDA is examining the disease from several perspectives. This article offers an overview of signs, symptoms, diagnosis and treatments for myasthenia gravis (MG), as well as information on drugs that people with MG should avoid.

A phase 1 clinical trial has begun in Turin, Italy, to test the safety of RG2833 in adults with Friedreich's ataxia

posted on March 15, 2012 - 11:00am
The biopharmaceutical company Repligen Corp., headquartered in Waltham, Mass., has launched a phase 1 clinical trial to test its experimental compound, RG2833, in adults with Friedreich's ataxia (FA). The trial is the first of a therapy specifically developed to treat the underlying molecular cause of FA. The phase 1 trial is being conducted at San Luigi Gonzaga University Hospital in Turin,...

The latest advances in diagnosis, medical management and the status of therapy development for neuromuscular diseases were covered at MDA's 2012 Clinical Conference

posted on March 9, 2012 - 2:28pm
The 2012 MDA Clinical Conference, held in Las Vegas March 4 -7, gave more than 500 attendees an opportunity to learn from top experts about the latest advances in diagnosis, medical management and emerging therapies for neuromuscular diseases.

Researchers have developed a new, two-step process for screening newborn babies for Duchenne MD and possibly other muscular dystrophies

posted on March 2, 2012 - 9:37am
Update 5/21/12: A podcast on this topic is now available; see Podcast Explores Newborn Screening for DMD.

Check out daily blogs from the conference, which will focus on genetics, immunology, best practices, clinic management and future therapies for neuromuscular diseases

posted on March 1, 2012 - 6:00am
Current trends and practices in the treatment of neuromuscular disease, and exciting new therapeutic developments will be the focus of MDA’s 2012 Clinical Conference March 4-7, at the South Point Hotel in Las Vegas. Although not open to the general public, the conference agenda and daily blogs about the proceedings will be available on the 2012 Clinical Conference website.

Knowing your exact genetic diagnosis does more than just satisfy your curiosity — it can impact family planning, disease management and participation in clinical trials

posted on February 28, 2012 - 2:02pm
Respondents to MDA’s Transitions Survey — in other words, people with a neuromuscular disease who are in their teens through late 30s — made it clear they had questions about the genetics of their disease, as well as questions about family planning and the value of diagnostic testing. MDA’s Genetic Counseling Webinar, which occurred Feb. 22, 2012, answers many of those questions.

If passed into law, the ABLE Act would create special savings accounts to be used for disability-related expenses without threatening other government benefits

posted on January 17, 2012 - 2:42pm

The pace of research can seem unreasonably slow; here are a few reasons why

posted on January 1, 2012 - 3:11pm
QUEST Vol. 19, No. 1
John Porter from the National Institutes of Health likes to start talks by noting, “It’s a great time to be a mouse with a neuromuscular disease.” Exciting research results are regularly reported, where a treatment appears to cure one neuromuscular disease or another in a mouse — yet there are few treatments available today for people with any of these diseases, and only a few treatments in human...